{"filings":[{"id":759757,"accession_number":"0001193125-26-249790","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-06-01T12:07:23+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Rallybio to merge with Avenzo Therapeutics; pre-merger Avenzo holders to own ~56.6% of combined co","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Avenzo stockholders expected to own ~56.6% of combined co; Rallybio stockholders ~2.8%; new investors in $215M concurrent financing ~40.6% on fully diluted basis.","Rallybio will distribute net cash to stockholders pre-closing; holders receive CVRs for potential proceeds from legacy asset sales.","Combined company led by Avenzo management: Dr. Athena Countouriotis as CEO, Scott Lipman as CFO; current Rallybio executives/directors expected to resign.","Merger requires Rallybio stockholder approval, reverse stock split, name change to Avenzo Therapeutics; closing conditions include $215M financing and no material adverse effect.","Support agreements from ~24.3% of Rallybio stockholders and ~78% of Avenzo stockholders; lock-up agreements for Avenzo insiders for 180 days post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95105,"accession_number":"0001193125-26-202601","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.02","1.01","9.01"],"status":"ready","headline":"Rallybio receives $50M termination fee after Candid merger terminates for UCB deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Candid Therapeutics terminated its merger with Rallybio to enter a Permitted Alternative Agreement with UCB S.A.","Rallybio entitled to $50,000,000 Parent Termination Fee plus $375,000 expense reimbursement, payable by May 4, 2026.","Rallybio, Candid and UCB entered a waiver releasing claims and waiving certain merger rights.","Rallybio intends to withdraw its Form S-4 registration statement filed for the merger.","The termination fee provides immediate cash, but the merger failure is a setback for Rallybio's strategic plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107940,"accession_number":"0001628280-26-022385","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rallybio CMO Steven Ryder departs immediately; severance tied to pending Candid merger","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Ryder, M.D., Chief Medical Officer, leaves Rallybio effective March 31, 2026.","Severance includes payments for without-cause termination; additional contingent on Candid merger close.","Equity awards remain outstanding and vest per Merger Agreement; exercisable 90 days post-close.","Pending business combination with Candid Therapeutics announced March 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107939,"accession_number":"0001193125-26-084444","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Rallybio agrees to reverse merger with Candid; Rallybio holders get ~3.65% of combined firm","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Rallybio pre-merger holders expected to own ~3.65% of combined company; Candid holders ~57.55%; financing investors ~38.80% (based on $505.5M raise).","Concurrent $505.5M private placement from accredited investors, shares convert to Rallybio common at closing.","Post-merger CEO will be Ken Song, current Candid Chairman/President/CEO; current Rallybio executives to resign.","Rallybio regained Nasdaq $1.00 bid compliance after 1-for-8 reverse stock split effective Feb 6, 2026.","Rallybio stockholders must approve share issuance (>20%), reverse split, name change to 'Candid Therapeutics, Inc.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107938,"accession_number":"0001739410-26-000010","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Rallybio announces 1-for-8 reverse stock split effective Feb 6, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-8 ratio approved by shareholders; effective 12:01 a.m. ET on Feb 6, 2026.","Shareholder vote: 34,507,021 for, 464,514 against, 11,939 abstain; no broker non-votes.","Post-split CUSIP changes to 75120L 209; trading symbol RLYB on Nasdaq remains unchanged.","Board selected 1-for-8 ratio from authorized range of 1-for-5 to 1-for-20 per shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124356,"accession_number":"0001739410-25-000131","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio posts Q3 net income of $16.0M on $20M REV102 sale; RLYB116 data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.2M vs $0.3M YoY; R&D expenses fell to $4.1M (from $8.2M); G&A $3.0M (from $4.1M).","Net income $16.0M ($0.36/share) vs net loss $11.5M in Q3 2024; includes $20M from sale of REV102 interest.","Cash and securities $59.3M as of Sept 30; expected to fund operations through 2027.","Completed Cohort 1 dosing of RLYB116 confirmatory PK/PD study; data on track for Q4 2025.","RLYB332 development plans being evaluated; preclinical data show superior PD vs comparator molecules."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":636000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141026,"accession_number":"0001193125-25-192749","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Rallybio fails Nasdaq bid price compliance; transfer to Capital Market grants extension to Feb 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Rallybio on Aug 26, 2025 of transfer to Capital Market; stock continues trading as RLYB.","Company failed to regain $1.00 minimum bid price by Aug 25, 2025 deadline; new compliance date is Feb 23, 2026.","If not compliant by Feb 23, 2026, Nasdaq will issue delisting notice; Rallybio may appeal or pursue reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141025,"accession_number":"0001739410-25-000108","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q2 net loss $9.7M, sells REV102 to Recursion for $25M; RLYB116 data Q3/Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.7M ($0.22/share) vs $16.2M in Q2 2024; revenue $0.2M.","Sold REV102 to Recursion for up to $25M, including $7.5M upfront equity; cash runway extended into mid-2027.","RLYB116 confirmatory PK/PD study dosing started; Cohort 1 and Cohort 2 topline data expected Q3 and Q4 2025.","RLYB212 program discontinued after Phase 2 PK data missed target concentrations.","Cash, equivalents and marketable securities $45.7M at June 30, 2025; with REV102 payment, runway into mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":424000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141024,"accession_number":"0001739410-25-000100","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Rallybio sells ENPP1 JV stake to Recursion for up to $25M; cash runway to mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront equity payment of $7.5M (1,457,952 Recursion shares); potential $12.5M contingent equity and $5M clinical milestone.","Rallybio eligible for low single-digit royalties on future net sales of REV102 (ENPP1 inhibitor for HPP).","Deal extends Rallybio's cash runway to mid-2027; company sharpens focus on RLYB116 confirmatory study topline data this year.","REV102 was in IND-enabling studies; Recursion gains full ownership to accelerate development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158803,"accession_number":"0001739410-25-000093","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rallybio enters into employment agreement with CMO Steven Ryder; base salary $531,227","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary $531,227 per year; target annual bonus of up to 40% of base salary.","Initial one-year term auto-renewing annually unless 60-day non-extension notice given.","Severance on non-cause/good reason termination: 12 months base salary and COBRA premiums.","Change-in-control severance: 1.5x (base + target bonus) paid over 18 months plus full vesting of time-based equity.","Non-compete and non-solicit covenants apply during employment and for one year post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158802,"accession_number":"0001739410-25-000089","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rallybio shareholders elect Mackay and Soteropoulos as directors, ratify Deloitte as auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Martin W. Mackay elected as Class I director with 23,833,701 for and 3,132,991 against.","Paula Soteropoulos elected as Class I director with 23,812,816 for and 3,153,701 against.","Ratification of Deloitte & Touche as independent auditor for FY2025: 34,632,324 for, 40,810 against, 1,758 abstentions.","Broker non-votes totaled 7,708,200 on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158801,"accession_number":"0001739410-25-000059","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q1 net loss $9.4M; discontinues RLYB212, cuts workforce 40%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.4M ($0.21 per share) vs $19.0M ($0.47) in Q1 2024; revenue $0.2M from J&J collaboration.","Cash, cash equivalents, and marketable securities $54.5M; runway into 1H 2027.","RLYB212 program discontinued after Phase 2 PK data missed target concentrations.","Workforce reduction of 40% (nine positions) with ~$1.7M in severance charges; substantially complete by end of Q2 2025.","RLYB116 confirmatory PK/PD study on track to start in Q2 2025; Cohort 1 data in Q3, Cohort 2 in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":212000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158800,"accession_number":"0001739410-25-000052","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rallybio discontinues RLYB212 for FNAIT after Phase 2 PK misses efficacy targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 PK results: RLYB212 concentrations near/ below assay LLoQ, missing minimum target of 3 ng/mL and predicted 6-10 ng/mL.","No further enrollment; safety follow-up of sentinel participant continues; dose adjustment not feasible.","RLYB116 confirmatory PK/PD study to initiate Q2 2025 with data from Cohorts 1 and 2 in 3Q/4Q 2025.","REV102 (ENPP1 inhibitor, JV with Recursion) in IND-enabling studies; Phase 1 expected 2026; preclinical data 2H 2025.","RLYB332 (long-acting matriptase-2 antibody) preclinical development ongoing for iron overload diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177207,"accession_number":"0001739410-25-000041","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rallybio reduces ATM offering cap from $100M to $9.55M under Sales Agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces aggregate offering price from $100,000,000 to $9,550,000.","As of March 13, 2025, no shares have been sold under the Sales Agreement.","TD Cowen receives up to 3.0% commission on gross proceeds in at-the-market sales.","Sales limited by public float rule: cannot exceed one-third of non-affiliate market value if public float <$75M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177206,"accession_number":"0001739410-25-000029","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q4 net loss $11M, cash $65.5M; key trial data readouts in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $11.0M ($0.25/share) vs $20.2M ($0.50/share) in Q4 2023; full-year loss $57.8M.","Revenue $38k in Q4 2024 from J&J collaboration; zero revenue in year ago period.","Cash, equivalents, and marketable securities $65.5M as of Dec 31, 2024; runway into 2H 2026.","RLYB212 Phase 2 sentinel participant dosed; PK/safety data from 2nd trimester expected Q2 2025, at delivery Q3 2025.","RLYB116 confirmatory PK/PD study to start Q2 2025; Cohorts 1 and 2 data in Q3/Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177205,"accession_number":"0001739410-25-000021","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Rallybio receives Nasdaq bid price deficiency notice; faces potential delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice on Feb 24, 2025: closing bid price below $1.00 for 30 consecutive business days.","Company has 180 days, until August 25, 2025, to regain compliance by closing at $1.00+ for 10 days.","If not cured, may qualify for additional 180-day period by transferring to Nasdaq Capital Market.","Failure to regain compliance could lead to delisting and potential appeal to Nasdaq Hearings Panel.","No immediate impact on trading; stock continues to list on Nasdaq under other requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193978,"accession_number":"0001739410-24-000132","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q3 net loss narrows to $11.5M; RLYB212 Phase 2 to screen in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.5M ($0.26/share) vs $18.4M ($0.45) in Q3 2023; revenue $0.3M from J&J collaboration.","Cash $75.1M as of Sep 30, 2024 provides runway into mid-2026; R&D expenses down 38% to $8.2M.","RLYB212 Phase 2 CTA approved by EMA and MHRA; screening for pregnant women at FNAIT risk to start Q4 2024.","RLYB116 manufacturing improvements completed; biomarker data suggests potential in PNH and APS beyond myasthenia gravis.","ENPP1 inhibitor candidate nomination with Exscientia on track for Dec 2024; preclinical data showed PPi reduction and improved bone mineralization."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":598000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210308,"accession_number":"0001739410-24-000121","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kush Parmar to resign from Rallybio Board effective Oct 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kush Parmar resigns from the Board and as Chair of the Nominating and Corporate Governance Committee.","Resignation effective October 31, 2024; not due to any dispute or disagreement with Rallybio.","No replacement for Parmar's Board seat announced as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210307,"accession_number":"0001739410-24-000114","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio Q2 net loss $16.2M; cash $88.6M; RLYB212 Phase 2 on track for Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $16.2M ($0.37/share) vs $18.6M ($0.46/share) in Q2 2023.","Revenue $0.3M from J&J collaboration; no revenue in prior year.","Cash, equivalents, and securities $88.6M as of June 30, expecting runway into mid-2026.","RLYB212 Phase 2 trial in pregnant women at risk of FNAIT remains on track to start Q4 2024.","Epidemiological analysis estimates >30,000 higher-risk pregnancies/year in North America and major European countries, 40% above prior estimates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":299000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210306,"accession_number":"0001739410-24-000105","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rallybio Executive Chairman Martin Mackay to resign employment, stay as Chairman and consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin Mackay will resign as Executive Chairman and employee effective Dec 31, 2024; no severance paid.","He will remain as Chairman of the Board; consulting agreement from Jan 1, 2025 to Jan 1, 2026 at $18,750/month.","Outstanding unvested time-based equity awards will vest immediately upon a Change of Control during consultancy.","Dr. Mackay eligible for 2024 annual bonus based on performance, paid at same time as employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228617,"accession_number":"0001739410-24-000098","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rallybio shareholders elect four Class III directors and ratify Deloitte as auditor.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Wendy K. Chung, Robert Hopfner, Ronald Hunt, and Hui Liu as Class III directors for terms expiring in 2027.","Broker non-votes totaled 4,647,512 on director elections, reflecting significant retail holder participation.","Ratified Deloitte & Touche as independent auditor for FY 2024 with 31,396,236 for, 32,355 against, and 7,173 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228616,"accession_number":"0001739410-24-000053","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rallybio posts Q1 net loss of $19.0M; cash $94.2M; on track for RLYB212 Phase 2 in 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.0M ($0.47 per share) vs $17.3M ($0.43 per share) in Q1 2023.","Cash, cash equivalents, and marketable securities of $94.2M as of March 31, 2024; runway into mid-2026.","Announced 45% workforce reduction in Feb 2024 to focus on RLYB212 and RLYB116.","Collaboration with Johnson & Johnson (Momenta) for FNAIT; received $6.6M equity investment.","Phase 2 trial of RLYB212 in pregnant women at risk for FNAIT on track for 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228615,"accession_number":"0001739410-24-000040","cik":1739410,"company_name":"Rallybio Corp","ticker":"RLYB","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Rallybio announces J&J collaboration with $0.5M upfront and $6.6M equity for FNAIT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with J&J: Rallybio receives $0.5M upfront, up to $3.7M milestones for FNAIT data sharing and awareness.","J&J affiliate JJDC invests $6.6M via purchase of 3.6M shares in private placement at ~$1.82/share.","Rallybio's RLYB212 (preventative for non-alloimmunized) and J&J's nipocalimab (for alloimmunized) target FNAIT; Phase 2 for RLYB212 expected H2 2024.","JJDC locked up from selling shares for 180 days; collaboration agreement expires April 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":76134230.06469373,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}